State Street Corp Acquires 526,028 Shares of Twist Bioscience Co. (NASDAQ:TWST)

State Street Corp lifted its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 19.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,167,353 shares of the company's stock after acquiring an additional 526,028 shares during the quarter. State Street Corp owned 5.41% of Twist Bioscience worth $143,101,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in TWST. Signaturefd LLC raised its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC purchased a new position in shares of Twist Bioscience in the second quarter worth about $43,000. Blue Trust Inc. increased its holdings in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after acquiring an additional 381 shares during the period.

Insider Activity

In related news, SVP Paula Green sold 860 shares of the stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the completion of the transaction, the senior vice president now directly owns 133,715 shares in the company, valued at $7,046,780.50. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 2,216 shares of the business's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $116,783.20. Following the sale, the chief executive officer now directly owns 674,718 shares in the company, valued at $35,557,638.60. The trade was a 0.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,787 shares of company stock worth $4,584,508 in the last quarter. 3.92% of the stock is owned by company insiders.

Twist Bioscience Price Performance

TWST traded up $0.11 on Friday, hitting $47.50. The company had a trading volume of 814,078 shares, compared to its average volume of 940,837. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The stock has a fifty day simple moving average of $44.94 and a 200-day simple moving average of $46.63. The firm has a market capitalization of $2.82 billion, a P/E ratio of -13.19 and a beta of 1.82.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TWST. Wolfe Research began coverage on Twist Bioscience in a research note on Friday. They issued an "outperform" rating and a $60.00 price target on the stock. Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Robert W. Baird increased their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research report on Tuesday, November 19th. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 19th. Finally, Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $51.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.